



# Elvitegravir

## Kinase Inhibitor

E1KS2001

**Kinase Inhibitor Name:** Elvitegravir

**Catalog Number:** E1KS2001

**Quantity:** 10mg


**M.Wt:** 447.88

**Formula:** C<sub>23</sub>H<sub>23</sub>ClFNO<sub>5</sub>

**Solubility:** DMSO ≥90 mg/mL    Water <1 mg/mL    Ethanol ≥90 mg/mL

**Stability:** 2 years    -20°C    Powder  
1 week    -4°C    in DMSO  
1 month    -80°C    in DMSO

**CAS No.:** 697761-98-1



### Biological Activity

Elvitegravir is a human immunodeficiency virus integrase inhibitor with EC<sub>50</sub> of 0.7, 2.8 and 1.4 for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD. Elvitegravir plays an essential role in the integration of proviral DNA into the host genome. Interestingly, elvitegravir also showed antiviral activity against murine leukemia virus (MLV) and simian immunodeficiency virus (SIV). EVG inhibited the integration of the HIV-based vector used as a positive control for the luciferase assay (EC<sub>50</sub> values of 0.8 nM), as observed in the MAGI assay with HIV-1IIIB. Elvitegravir suppressed the replication of MLV infection (EC<sub>50</sub> values of 5.8 nM) as well as that of the primate retrovirus SIV (0.5 nM), indicating that IN inhibitors have antiviral activity against a broad range of retroviruses. <sup>[1][2][3]</sup>

### References

Molecular mechanisms in retrovirus DNA integration Ernest Asante-Appiah, Anna Marie Skalka  
Antiviral Research 1997;36 :139–156

A quantitative assay for HIV DNA integration in vivo SCOTT L. BUTLER, MARK S.T. HANSEN, et al.  
NATURE MEDICINE MAY 2001;7:631-634

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) Kazuya Shimura, Eiichi Kodama, et al. JOURNAL OF VIROLOGY Jan. 2008;82:764–774

**The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.**

**For Research Use Only**